期刊文献+

孟鲁司特治疗5~14岁哮喘患儿的随机双盲对照研究 被引量:6

Montelukast for Chronic Asthma in 5 to 14 Year Old Children:A Randomized,Double-Blind Trial
下载PDF
导出
摘要 目的:研究白三烯受体拮抗剂孟鲁司特治疗5~14岁哮喘患儿的临床疗效。方法:84例5~14岁哮喘患儿按照随机双盲对照研究分为两组各42例,其中治疗组给予孟鲁司特5 mg睡前口服,对照组给予安慰剂睡前口服,记录两组患儿晨间最大呼气峰流速值(PEFam)、晚间最大呼气峰流速值(PEFpm)、第1秒用力呼气量(FEV1)、日间及夜间哮喘症状评分、咳嗽评分、夜间憋醒天数、使用β2受体激动剂天数。结果:治疗组肺功能各项指标PEFam(356.23±11.32)L/min,PEFpm(334.32±12.34)L/min,FEV1(1.64±0.78)L,FEV1/FVC(87.3±7.76)%;对照组肺功能各项指标PEFam(323.67±10.32)L/min,PEFpm(298.32±11.54)L/min,FEV1(1.23±0.56)L,FEV1/FVC(81.5±7.97)%。治疗组肺功能各项指标改善情况明显优于对照组,两组比较差异均有统计学意义(P<0.05)。并且治疗组日间哮喘症状评分、夜间哮喘症状评分、咳嗽评分、夜间憋醒天数、使用β2受体激动剂天数明显少于对照组,两组比较差异均有统计学意义(P<0.01)。两组患儿均无严重不良反应发生。结论:孟鲁司特能显著改善5~14岁哮喘患儿的肺功能。 Objective: To determine the clinical effect of montelukast, a leukotriene receptor antagonist, in 5 to 14 year old children with asthma. Methods: A total of 84 children patients according to a randomized double-blind control study were divided into two groups. Patients were given montelukast (5 mg chewable tablet) or matching-image placebo once daily at bedtime for 4 weeks. Morning peak expiratory flow rate value (PEFam) , maximum peak flow values in the evening (PEFpm), first second forced expiratory volume ( FEV1 ) , daytime and nocturnal asthma symptom score, cough score, night hold up days and the course of using beta 2 agonists in two groups were recorded. Results: In the treatment group, lung function indexes such as PEFam (356.23±11.32) L/min, PEFpm (334.32±12.34) L/min, FEV1 (1.64±0.78) L and FEV1/FVC (87.3 ±7.76) % was significantly better than those in the observation group (PEFam (323.67±10.32)L/min, PEFpm (298.32±11.54)L/min, FEV1 (1.23±0.56)L, FEV1/FVC (81.5±7.97)%. The difference was statistically significant (P〈0. 05 ). The daytime asthma symptom score, nocturnal asthma symptom score, cough score, night hold up days, and the course of using beta 2 agonists in treatment group were significantly lower than those in the control group, there were significant differences (P〈 0.01 ). Both groups of patients had no severe adverse reaction. Conclusions: Montelukast improves lung function in 5 to 14 year old children with chronic asthma
作者 于晗澍
出处 《儿科药学杂志》 CAS 2012年第10期4-7,共4页 Journal of Pediatric Pharmacy
关键词 孟鲁司特 哮喘 儿童 肺功能 Montelukast Asthma Children Lung function
  • 相关文献

参考文献8

  • 1Krishnan JA, Bender BG, Wamboldt FS, et al. Adherence to inhaled corticosteroids : an ancillary study of the Childhood Asthma Management Program clinical trial [ J ]. J Allergy Clin hnmunol, 2012, 129(l): 112-118. 被引量:1
  • 2Hernando SV, Rodrlguez M, Ayala SJ, et al. Montelukast in early childhood asthma. Predict value of IgG in clinical reply in children 2 to 5 years old [ J ] ? Allergol Immunopathol ( Madr), 2004, 32 (4) : 204-211. 被引量:1
  • 3儿童支气管哮喘诊断与防治指南[J].中华儿科杂志,2008,46(10):745-753. 被引量:2521
  • 4Muraki M, [mbe S, Santo H, et al. Effects of a cysteinyl leukotriene dual 1/2 receptor antagonist on antigen-induced airway hypersensitivity and airway inflammation in a guinea pig asthma model [ J ]. Int Arch Allergy lmmunol, 2011, 155 ( l ) : 90-95. 被引量:1
  • 5刘纯,陈久艳,尚尔宁.干扰素α1b联合孟鲁司特钠治疗小儿喘息性支气管炎84例疗效观察[J].儿科药学杂志,2011,17(6):29-31. 被引量:24
  • 6Visitsunthorn N, Chirdjirapong V, Santadilog S, et al. The effect of montelukast on bronchial hyperreactivity and lung function in asthmatic children aged 6-13 years [ J ]. Asian Pac J Allergy hnmunol, 2011, 29(2) : 127-133. 被引量:1
  • 7Schaper C, Noga O, Koch B, et al. Anti-inflammatory properties of montelukast, a leukotriene receptor antagonist in patients with asthma and nasal polyposis [ J]. J Investig Allergol Clin Immunol,2011, 21(1): 51-58. 被引量:1
  • 8Bellecoste V, Devouassoux G, Pacheco Y. Montelukast in the treatment of mild to moderate persistent asthma [ J ]. Rev MalRespir, 2011, 28(6): 706-729. 被引量:1

二级参考文献11

共引文献2542

同被引文献50

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部